v3.26.3
Inventory - Narrative (Details) - USD ($)
$ in Millions
3 Months Ended 9 Months Ended
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
May 31, 2026
May 14, 2026
Sep. 26, 2023
Inventory [Line Items]              
Net income $ (20.6) $ 466.5 $ 396.4 $ 1,341.8      
Cost of sales, excluding amortization and impairment of acquired intangible assets 748.4 674.4 2,186.3 1,908.7      
EMPAVELI and SYFOVRE              
Inventory [Line Items]              
Inventory*         $ 681.0    
EMPAVELI and SYFOVRE | Business Combination, Pro Forma Information, Nonrecurring Adjustment, Inventory, Fair Value Adjustment              
Inventory [Line Items]              
Net income 541.5            
Apellis Pharmaceuticals, Inc.              
Inventory [Line Items]              
Inventory*           $ 681.0  
Apellis Pharmaceuticals, Inc. | Business Combination, Pro Forma Information, Nonrecurring Adjustment, Inventory, Fair Value Adjustment              
Inventory [Line Items]              
Net income 100.0   169.7        
Reata Pharmaceuticals, Inc              
Inventory [Line Items]              
Inventory*             $ 1,300.0
Reata Pharmaceuticals, Inc | Business Combination, Pro Forma Information, Nonrecurring Adjustment, Inventory, Fair Value Adjustment              
Inventory [Line Items]              
Net income 97.2 $ 61.5 337.9 $ 165.4      
Reata Pharmaceuticals, Inc | Business Combination, Pro Forma Information, Nonrecurring Adjustment, Inventory, Fair Value Adjustment | Clinical Inventory              
Inventory [Line Items]              
Cost of sales, excluding amortization and impairment of acquired intangible assets $ 0.0   $ 94.3